Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance.

Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, Nedderman ANR, Prakash C, Runge F, Scheible H, Spracklin DK, Swart P, Tse S, Yuan J, Obach RS.

Drug Metab Dispos. 2018 Jun;46(6):865-878. doi: 10.1124/dmd.117.079848. Epub 2018 Feb 27. Review.

PMID:
29487142
2.

Simultaneous qualitative and quantitative metabolism data generation: a convenient marriage?

Nedderman AN, Savage ME, Gleave M, Haynes JJ.

Bioanalysis. 2012 May;4(9):1009-12. doi: 10.4155/bio.12.32. No abstract available.

PMID:
22612682
3.

Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?

Obach RS, Nedderman AN, Smith DA.

Xenobiotica. 2012 Jan;42(1):46-56. doi: 10.3109/00498254.2011.621985. Epub 2011 Oct 12. Review.

PMID:
21992031
4.

From definition to implementation: a cross-industry perspective of past, current and future MIST strategies.

Nedderman AN, Dear GJ, North S, Obach RS, Higton D.

Xenobiotica. 2011 Aug;41(8):605-22. doi: 10.3109/00498254.2011.562330. Epub 2011 Mar 29. Review.

PMID:
21446837
5.

Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis.

Nedderman AN, Wright P.

Bioanalysis. 2010 Jul;2(7):1235-48. doi: 10.4155/bio.10.71. Review.

PMID:
21083237
6.

Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.

Vourvahis M, Gleave M, Nedderman AN, Hyland R, Gardner I, Howard M, Kempshall S, Collins C, LaBadie R.

Drug Metab Dispos. 2010 May;38(5):789-800. doi: 10.1124/dmd.109.031252. Epub 2010 Feb 2.

PMID:
20124396
7.

Metabolites in safety testing: metabolite identification strategies in discovery and development.

Nedderman AN.

Biopharm Drug Dispos. 2009 May;30(4):153-62. doi: 10.1002/bdd.660.

PMID:
19544286
8.

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.

Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:60-7. doi: 10.1111/j.1365-2125.2008.03137.x.

9.

Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity.

Allan GA, Gedge JI, Nedderman AN, Roffey SJ, Small HF, Webster R.

Xenobiotica. 2006 May;36(5):399-418.

PMID:
16854779
10.

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA.

Drug Metab Dispos. 2005 Apr;33(4):587-95. Epub 2005 Jan 13.

PMID:
15650075
11.

The use of 96-well Scintiplates to facilitate definitive metabolism studies for drug candidates.

Nedderman AN, Savage ME, White KL, Walker DK.

J Pharm Biomed Anal. 2004 Feb 18;34(3):607-17.

PMID:
15127817
12.

A sensitive HPLC-MS-MS assay for quantitative determination of midazolam in dog plasma.

Harris SR, Gedge JI, Nedderman AN, Roffey SJ, Savage M.

J Pharm Biomed Anal. 2004 Apr 1;35(1):127-34.

PMID:
15030887
13.

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N.

Drug Metab Dispos. 2003 Jun;31(6):731-41.

PMID:
12756205
14.
15.
16.

Molecular basis for methoxyamine initiated mutagenesis. 1H nuclear magnetic resonance studies of base-modified oligodeoxynucleotides.

Stone MJ, Nedderman AN, Williams DH, Lin PK, Brown DM.

J Mol Biol. 1991 Dec 5;222(3):711-23.

PMID:
1660932

Supplemental Content

Loading ...
Support Center